Source: PHARMAC
Information on what the Immunisation Advisory Committee will be considering at its meeting in November 2025.
Applications
Nirsevimab (branded as BEYFORTUS) for the prevention of RSV in infants
The Committee will discuss an application for funding nirsevimab for the prevention of respiratory syncytial virus (RSV) in infants.
Members of the Respiratory Advisory Committee will also join for this discussion.
Application for Nirsevimab (BEYFORTUS) for infant RSV protection(external link)
RSVPreF3 vaccine (branded as Arexvy) for low respiratory tract disease
The Committee will discuss an updated application for RSVPreF3 Vaccine (Arexvy) for the prevention of lower respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older.
Members of the Respiratory Advisory Committee will also join for this discussion.
Application for RSVPreF3 (Arexvy)(external link)
Pneumococcal polysaccharide conjugate vaccine, 20-valent (branded as Prevenar 20) for the prevention of invasive pneumococcal disease
The Committee will discuss an application for Pneumococcal 20-valent conjugate vaccine for the prevention of invasive pneumococcal disease in paediatric populations and high-risk adults.
Application for Pneumococcal 20-valent conjugate vaccine (Prevenar 20)(external link)
Fluad vaccine and Flucelvax vaccine for influenza
The Committee will discuss new information about the applications for Fluad influenza vaccine for people 65 years of age and over and Flucelvax influenza vaccine for people 6 months to under 65 years of age.
Application for Flucelvax vaccine(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.
